Search results
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 21 hours agoAstraZeneca (AZN 0.91%), recognized as the world's sixth-largest pharmaceutical entity by market...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
The Motley Fool via AOL· 2 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 12 hours agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 2 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Market Watch· 21 hours agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 20 hours agoOn Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a market...
Analyst Report: AstraZeneca PLC
Argus Research via Yahoo Finance· 21 hours agoAstraZeneca is a British-Swedish company with its main headquarters in the U.K. and regional headquarters in Sweden and the U.S. It focuses on treatments for respiratory, ...
AstraZeneca stock upgraded by Goldman, 27% upside seen By Investing.com
Investing.com· 23 hours agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN)...
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 9 hours agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lifted by Hsbc Holdings PLC
ETF DAILY NEWS· 22 hours agoHsbc Holdings PLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the ...
